Boltz PBC
Boltz, PBC provides foundational AI models and an integrated platform for biomolecular structure prediction, affinity estimation, and generative design across small molecules and biologics. Its open-source models, Boltz-2 and BoltzGen, have been downloaded over 5 million times and are used by more than 1,000 companies, including top 20 pharma firms. The platform integrates with Codex and Claude Science for deployment within existing scientific workflows.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Biotechnology
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Drug discovery pipelines require accurate prediction of biomolecular structures and interactions, yet existing tools often lack the precision, integration, and accessibility needed for rapid preclinical decision-making. Scientists face steep barriers in applying advanced AI models to small-molecule and biologics design without deep computational expertise or proprietary infrastructure.
Solution
Boltz, PBC provides foundational AI models and an integrated platform for biomolecular research, covering structure prediction, affinity estimation, and generative design across multiple modalities. The company's open-source models, including Boltz-2 and BoltzGen, are widely adopted in the pharmaceutical industry, while its commercial platform integrates these models with proprietary generative workflows, intuitive user interfaces, and high-performance compute. Through strategic collaborations, Boltz refines its models on partner-specific historical data to create exclusive, state-of-the-art models tailored to preclinical discovery programs. Scientists gain access to accurate predictions and generative capabilities directly within their existing tools, including Codex and Claude Science integrations.
Target Audience
Primary customers are pharmaceutical and biotechnology companies using AI-driven approaches for preclinical drug discovery, as well as individual scientists and research institutions leveraging open-source biomolecular AI tools.
Features
- Open-source biomolecular foundation models (Boltz-2, BoltzGen) for protein design, structure prediction, and affinity estimation
- Integrated platform combining generative AI workflows, user interfaces, and high-performance compute for deployment-ready use
- Multi-modality support for small-molecule and biologics design across diverse disease areas
- Integrations with Codex and Claude Science, enabling use within widely adopted scientific AI tools
- Custom model development and workflow refinement through strategic partnerships with pharmaceutical companies
- Over 5 million downloads and adoption by 100,000+ scientists across 1,000+ companies, including top 20 pharma firms